Advertisement
MLYS vs ROIV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLYS is a Hold and ROIV is a StrongBuy.
MLYS's RSI Indicator descends into oversold zone
The RSI Indicator for MLYS moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLYS advanced for three days, in 170 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
MLYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MLYS as a result. In 46 of 60 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for MLYS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MLYS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.460) is normal, around the industry mean (3.498). P/E Ratio (-3.650) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. MLYS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLYS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ROIV's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ROIV turned positive on October 21, 2026. Looking at past instances where ROIV's MACD turned positive, the stock continued to rise in 46 of 57 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ROIV as a result. In 72 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
ROIV moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ROIV crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +5.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where ROIV advanced for three days, in 230 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ROIV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
ROIV broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ROIV entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.637) is normal, around the industry mean (3.498). ROIV has a moderately low P/E Ratio (-108.000) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. ROIV's P/S Ratio (3333.333) is slightly higher than the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ROIV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ROIV | ||
|---|---|---|
OUTLOOK RATING 1..100 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 6 | |
SMR RATING 1..100 | 92 | |
PRICE GROWTH RATING 1..100 | 36 | |
P/E GROWTH RATING 1..100 | 63 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| MLYS | ROIV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 2 days ago 73% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 78% |
| Advances ODDS (%) | 3 days ago 85% | 2 days ago 78% |
| Declines ODDS (%) | 10 days ago 85% | 10 days ago 70% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 72% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MLYS’s FA Score shows that 1 FA rating(s) are green while ROIV’s FA Score has 2 green FA rating(s).
- MLYS’s FA Score: 1 green, 4 red.
- ROIV’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MLYS’s TA Score shows that 4 TA indicator(s) are bullish while ROIV’s TA Score has 5 bullish TA indicator(s).
- MLYS’s TA Score: 4 bullish, 4 bearish.
- ROIV’s TA Score: 5 bullish, 5 bearish.
Price Growth
MLYS (@Biotechnology) experienced а -2.94% price change this week, while ROIV (@Biotechnology) price change was +14.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ROIV is expected to report earnings on Feb 15, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MLYS and
Correlation & Price change
A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with EDIT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To MLYS | 1D Price Change % | ||
|---|---|---|---|---|
| MLYS | 100% | -1.83% | ||
| EDIT - MLYS | 46% Loosely correlated | -8.91% | ||
| NKTX - MLYS | 43% Loosely correlated | -15.09% | ||
| TSHA - MLYS | 43% Loosely correlated | -2.17% | ||
| DNLI - MLYS | 43% Loosely correlated | -2.36% | ||
| IKT - MLYS | 43% Loosely correlated | -7.74% | ||
More | ||||
ROIV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.
| Ticker / NAME | Correlation To ROIV | 1D Price Change % | ||
|---|---|---|---|---|
| ROIV | 100% | +1.28% | ||
| IMVT - ROIV | 65% Loosely correlated | +1.59% | ||
| IMTX - ROIV | 45% Loosely correlated | -0.16% | ||
| DNTH - ROIV | 44% Loosely correlated | -1.32% | ||
| MLYS - ROIV | 43% Loosely correlated | -1.83% | ||
| AXON - ROIV | 43% Loosely correlated | -0.21% | ||
More | ||||